Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 13;11(1):10283.
doi: 10.1038/s41598-021-89749-5.

NFL strongly correlates with TNF-R1 in the plasma of AD patients, but not with cognitive decline

Constance Delaby  1   2 , A Julian  3   4   5 , G Page  3 , S Ragot  5 , Sylvain Lehmann  6 , M Paccalin  3   4   5
Affiliations

NFL strongly correlates with TNF-R1 in the plasma of AD patients, but not with cognitive decline

Constance Delaby et al. Sci Rep. .

Abstract

Peripheral inflammation mechanisms involved in Alzheimer's disease (AD) have yet to be accurately characterized and the identification of blood biomarker profiles could help predict cognitive decline and optimize patient care. Blood biomarkers described to date have failed to provide a consensus signature, which is mainly due to the heterogeneity of the methods used or the cohort. The present work aims to describe the potential informativity of peripheral inflammation in AD, focusing in particular on the potential association between the level of plasma neurofilament light (NFL), peripheral inflammation (by quantifying IL-1β, IL-6, TNFα, CCL5, TNF-R1, sIL-6R, TIMP-1, IL-8 in blood) and cognitive decline (assessed by the MMSE and ADAScog scales) through a 2-year follow-up of 40 AD patients from the Cytocogma cohort (CHU Poitiers, Pr M. Paccalin). Our results show for the first time a strong correlation between plasma NFL and TNF-R1 at each time of follow-up (baseline, 12 and 24 months), thus opening an interesting perspective for the prognosis of AD patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Heneka MT, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405. doi: 10.1016/S1474-4422(15)70016-5. - DOI - PMC - PubMed
    1. Goldeck D, Witkowski JM, Fülop T, Pawelec G. Peripheral immune signatures in Alzheimer disease. Curr. Alzheimer Res. 2016;13:739–749. doi: 10.2174/1567205013666160222112444. - DOI - PubMed
    1. Paouri E, Georgopoulos S. Systemic and CNS inflammation crosstalk: Implications for Alzheimer’s disease. Curr. Alzheimer Res. 2019;16:559–574. doi: 10.2174/1567205016666190321154618. - DOI - PubMed
    1. Cuello AC. Early and late CNS inflammation in Alzheimer’s disease: Two extremes of a continuum? Trends Pharmacol. Sci. 2017;38:956–966. doi: 10.1016/j.tips.2017.07.005. - DOI - PubMed
    1. Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer’s disease; A source of heterogeneity and target for personalized therapy. Neuroscience. 2015;302:103–111. doi: 10.1016/j.neuroscience.2014.09.061. - DOI - PMC - PubMed